In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer, The Chase Group utilized its knowledge of the life sciences industry and vast network to successfully fill this key leadership position. Dr. Juergen Froehlich brings a broad range of therapeutic planning and hands-on execution across all phases of clinical development with an extensive track record of successful development projects and oversight. The Chase Group appreciated the partnership with Arcturus to find the executive leader who would help them make a positive impact through the advancement of mRNA medicines and the design and utilization of lipid-mediated drug delivery systems. For more information on how The Chase Group can assist in building your executive team, visit www.chasegroup.com.
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer, The Chase Group utilized its knowledge of the life sciences industry and vast network to successfully fill this key leadership position. Dr. Juergen Froehlich brings a broad range of therapeutic planning and hands-on execution across all phases of clinical development with an extensive track record of successful development projects and oversight. The Chase Group appreciated the partnership with Arcturus to find the executive leader who would help them make a positive impact through the advancement of mRNA medicines and the design and utilization of lipid-mediated drug delivery systems. For more information on how The Chase Group can assist in building your executive team, visit www.chasegroup.com.- Categories: Life Sciences
Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Ami Claxton, MS, PhD has joined Ionis Pharmaceuticals, Inc. as Director, Global HEOR Rare Disease Immunology. She will play a critical and significant role as…
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years…
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…